This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
After over a decade of multiple sclerosis (MS) therapies with only modest efficacy and inconvenient administration, the monoclonal antibody natalizumab was a welcomed addition to the MS treatment armamentarium. Natalizumab's efficacy included a 67% reduction in clinical relapses, a 42% reduction in disability progression, and a 92% reduction in gadolinium-enhancing lesions over 2 years, all compared to placebo.1 The euphoria surrounding this VLA-4 adhesion molecule antagonist was dampened when progressive multifocal leukoencephalopathy was identified as a rare, late complication of natalizumab treatment, with an estimated incidence of 1:1,000 over 18 months of therapy.
In this issue of Neurology®, Vellinga et al.2 present additional data on natalizumab which suggest that patients with MS may have rebound in MRI activity, although not clinical relapses, after discontinuation of natalizumab. The authors evaluated 21 patients enrolled in the natalizumab phase III clinical trials in their center. They compared new T2 lesions on brain MRI over a 7- to 54-month period prior to treatment with natalizumab, and compared that to a 15-month period after treatment discontinuation. They found that lesion activity increased threefold between the two periods, and this increase was almost entirely driven by patients who received only one to eight infusions (median two). Patients who received 30 to 37 infusions had very similar MRI activity before and after treatment. These findings are intriguing, although significant limitations include …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
